MS
PLRX icon

Maven Securities’s Pliant Therapeutics PLRX Stock Holding History

Maven Securities’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-75,000
Closed -$2M – 1011
2023
Q1 		$2M Buy
+75,000
New +$2.14M 0.04% 298
2020
Q3 		– Sell
-7,800
Closed -$253K – 723
2020
Q2 		$253K Buy
+7,800
New +$207K 0.02% 452

Other funds holding PLRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Maven Securities's PLRX Position: Q2 2023 in Review

Maven Securities sold out of Pliant Therapeutics (PLRX) in Q2 2023, closing a stake of 75,000 shares — an estimated $2M sold.

Maven Securities first reported a position in PLRX in Q2 2020 and held it in 2 quarters. The position peaked at $2M in Q1 2023. 144 funds tracked by Wall St. Rank hold PLRX as of Q2 2023.

  • Maven Securities reported no remaining Pliant Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Maven Securities sold 75,000 Pliant Therapeutics shares in Q2 2023, an estimated $2M.
  • Maven Securities first reported a position in Pliant Therapeutics in Q2 2020 and held it in 2 quarters.
  • Maven Securities's Pliant Therapeutics position peaked at $2M in Q1 2023.
  • 144 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2023.

Based on Maven Securities's 13F filing for Q2 2023, filed 4 Aug 2023.